Kanamori, Sato et al. develop SOF10, a humanized antibody that selectively blocks protease- and integrin αvβ8-mediated latent TGF-β1 activation. This selective blockade reduces fibrosis in multiple disease models, improves renal function, enhances anti-tumor immunity, and demonstrates safety in preclinical studies.
- Masakazu Kanamori
- Izumi Sato
- Hideaki Shimada
